guest ::
| Home > Publications Database > Daratumumab for treatment-refractory antibody-mediated diseases in neurology. > print |
| Home > Publications Database > Daratumumab for treatment-refractory antibody-mediated diseases in neurology. > print |
| 001 | 163492 | ||
| 005 | 20240324003433.0 | ||
| 024 | 7 | _ | |a 10.1111/ene.15266 |2 doi |
| 024 | 7 | _ | |a pmid:35098616 |2 pmid |
| 024 | 7 | _ | |a 1351-5101 |2 ISSN |
| 024 | 7 | _ | |a 1468-1331 |2 ISSN |
| 024 | 7 | _ | |a 1471-0552 |2 ISSN |
| 024 | 7 | _ | |a altmetric:156297705 |2 altmetric |
| 037 | _ | _ | |a DZNE-2022-00252 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Scheibe, Franziska |0 P:(DE-2719)9000850 |b 0 |u dzne |
| 245 | _ | _ | |a Daratumumab for treatment-refractory antibody-mediated diseases in neurology. |
| 260 | _ | _ | |a Oxford |c 2022 |b Blackwell Science |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1655203375_924 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a ISSN 1468-1331 not unique: **2 hits**. (CC BY-NC-ND) |
| 520 | _ | _ | |a A fraction of patients with antibody-mediated autoimmune diseases remain unresponsive to first-/second-line and sometimes even to escalation immunotherapies. Because these patients are still affected by poor outcome and increased mortality, we investigated the safety and efficacy of the plasma cell-depleting anti-CD38 antibody daratumumab in life-threatening, antibody-mediated autoimmune diseases.In this retrospective, single-center case series, seven patients with autoantibody-driven neurological autoimmune diseases (autoimmune encephalitis, n = 5; neurofascin antibody-associated chronic inflammatory demyelinating polyneuropathy associated with sporadic late onset nemaline myopathy, n = 1; seronegative myasthenia gravis, n = 1) unresponsive to a median of four (range = 4-9) immunotherapies were treated with four to 20 cycles of 16 mg/kg daratumumab.Daratumumab allowed a substantial clinical improvement in all patients, as measured by modified Rankin Scale (mRS; before treatment: mRS =5, n = 7; after treatment: median mRS =4, range = 0-5), Clinical Assessment Scale in Autoimmune Encephalitis (from median 21 to 3 points, n = 5), Inflammatory Neuropathy Cause and Treatment disability score (from 7 to 0 points, n = 1), and Quantitative Myasthenia Gravis score (from 16 to 8 points, n = 1). Daratumumab induced a substantial reduction of disease-specific autoreactive antibodies, total IgG (serum, 66%, n = 7; cerebrospinal fluid, 58%, n = 5), and vaccine-induced titers for rubella (50%) and tetanus toxoid (74%). Treatment-related toxicities Grade 3 or higher occurred in five patients, including one death.Our findings suggest that daratumumab provided a clinically relevant depletion of autoreactive long-lived plasma cells, identifying plasma cell-targeted therapies as promising escalation therapy for highly active, otherwise treatment-refractory autoantibody-mediated neurological diseases. |
| 536 | _ | _ | |a 353 - Clinical and Health Care Research (POF4-353) |0 G:(DE-HGF)POF4-353 |c POF4-353 |f POF IV |x 0 |
| 542 | _ | _ | |i 2022-02-10 |2 Crossref |u http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| 542 | _ | _ | |i 2022-02-10 |2 Crossref |u http://doi.wiley.com/10.1002/tdm_license_1.1 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de |
| 650 | _ | 7 | |a CIDP |2 Other |
| 650 | _ | 7 | |a autoimmune encephalitis |2 Other |
| 650 | _ | 7 | |a daratumumab |2 Other |
| 650 | _ | 7 | |a myasthenia gravis |2 Other |
| 650 | _ | 7 | |a sporadic late onset nemaline myopathy |2 Other |
| 650 | _ | 2 | |a Antibodies, Monoclonal |2 MeSH |
| 650 | _ | 2 | |a Autoantibodies |2 MeSH |
| 650 | _ | 2 | |a Encephalitis |2 MeSH |
| 650 | _ | 2 | |a Hashimoto Disease |2 MeSH |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Myasthenia Gravis |2 MeSH |
| 650 | _ | 2 | |a Nervous System Diseases: drug therapy |2 MeSH |
| 650 | _ | 2 | |a Neurology |2 MeSH |
| 650 | _ | 2 | |a Retrospective Studies |2 MeSH |
| 700 | 1 | _ | |a Ostendorf, Lennard |0 0000-0003-3553-6406 |b 1 |
| 700 | 1 | _ | |a Prüss, Harald |0 P:(DE-2719)2810931 |b 2 |u dzne |
| 700 | 1 | _ | |a Radbruch, Helena |b 3 |
| 700 | 1 | _ | |a Aschman, Tom |b 4 |
| 700 | 1 | _ | |a Hoffmann, Sarah |b 5 |
| 700 | 1 | _ | |a Blau, Igor-Wolfgang |b 6 |
| 700 | 1 | _ | |a Meisel, Christian |b 7 |
| 700 | 1 | _ | |a Alexander, Tobias |b 8 |
| 700 | 1 | _ | |a Meisel, Andreas |b 9 |
| 773 | 1 | 8 | |a 10.1111/ene.15266 |b Wiley |d 2022-02-10 |n 6 |p 1847-1854 |3 journal-article |2 Crossref |t European Journal of Neurology |v 29 |y 2022 |x 1351-5101 |
| 773 | _ | _ | |a 10.1111/ene.15266 |g p. ene.15266 |0 PERI:(DE-600)2020241-6 |n 6 |p 1847-1854 |t European journal of neurology |v 29 |y 2022 |x 1351-5101 |
| 856 | 4 | _ | |y OpenAccess |u https://pub.dzne.de/record/163492/files/DZNE-2022-00252.pdf |
| 856 | 4 | _ | |y OpenAccess |x pdfa |u https://pub.dzne.de/record/163492/files/DZNE-2022-00252.pdf?subformat=pdfa |
| 909 | C | O | |o oai:pub.dzne.de:163492 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 0 |6 P:(DE-2719)9000850 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 2 |6 P:(DE-2719)2810931 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-353 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Clinical and Health Care Research |x 0 |
| 914 | 1 | _ | |y 2022 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2022-11-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2022-11-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2022-11-11 |
| 915 | _ | _ | |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0 |0 LIC:(DE-HGF)CCBYNCND4 |2 HGFVOC |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b EUR J NEUROL : 2021 |d 2022-11-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-11 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2022-11-11 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b EUR J NEUROL : 2021 |d 2022-11-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2022-11-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-11 |
| 920 | 1 | _ | |0 I:(DE-2719)1810003 |k AG Prüß |l Autoimmune Enzephalopathies |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-2719)1810003 |
| 980 | 1 | _ | |a FullTexts |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1016/S1474-4422(12)70310-1 |2 Crossref |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1038/nrrheum.2011.1 |2 Crossref |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1212/WNL.0000000000003536 |2 Crossref |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.3389/fneur.2020.602102 |2 Crossref |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1007/s00415-019-09585-6 |2 Crossref |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1007/s00415-017-8599-4 |2 Crossref |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1182/blood-2015-12-687749 |2 Crossref |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1182/bloodadvances.2018020883 |2 Crossref |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1056/NEJMoa2023325 |2 Crossref |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1056/NEJMra1510062 |2 Crossref |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1056/NEJMoa1506348 |2 Crossref |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1056/NEJMoa1817249 |2 Crossref |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1002/ana.25421 |2 Crossref |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1002/mus.24207 |2 Crossref |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1212/01.WNL.0000163988.28892.79 |2 Crossref |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1016/j.cell.2020.09.049 |2 Crossref |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1136/annrheumdis-2014-206016 |2 Crossref |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|